Drug Development
Following rusfertide’s triumphant Phase III trial last year, Protagonist must decide how involved to be in future development. Hundreds of millions of dollars are on the line.
FEATURED STORIES
The prevalence of serious inflammatory safety issues such as cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome limits the reach of these transformative cancer therapies.
After years stuck in the “doldrums,” the biopharma sector is in a “very good place” heading into the new year, analysts told BioSpace, with both rare and chronic diseases headlining investor and R&D interest as JPM26 kicks off.
Recent breakthroughs and three decades of progress in treating Huntington’s disease
Subscribe to ClinicaSpace
Clinical trial results, research news, the latest in cancer and cell and gene therapy, in your inbox every Monday
THE LATEST
The FDA placed a clinical hold on Entrada’s experimental DMD candidate.
The FDA lifted its partial clinical hold on bluebird’s experimental sickle cell disease gene therapy for patients younger than 18.
Psychedelic and psychedelic-assisted therapies in the neuropsychiatric space have stalled for decades.
Madrigal’s NASH drug hits the mark in late-stage trial.
Ocugen gets the go-ahead from the FDA to trial its late-stage regenerative cell therapy.
Astellas’ zolbetuximab hit the mark in a second late-stage trial in Claudin-18.2-positive gastric cancer.
Covalent biologic company Enlaza launches with $61M in seed financing.
Lilly digs deeper into metabolic diseases via GPCR partnership with Sosei.
Third Harmonic Bio drops its Phase 1b asset.
While showing early promise, Senolytics is a new field and most of the research is still in academic centers – most notably, the Mayo Clinic.